Satralizumab
Satralizumab is listed in the FDA National Drug Code directory with 2 NDC codes, marketed under brand name including Enspryng. Available dosage form: injection, solution.
Drug Details
- Generic Name
- Satralizumab
- Brand Names
- Enspryng
- Application Number
- BLA761149
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- NDC Codes
- 2
- Dosage Forms
- INJECTION, SOLUTION
- Routes
- SUBCUTANEOUS
- Active Ingredients
- SATRALIZUMAB
Indications and Usage
1 INDICATIONS AND USAGE ENSPRYNG is indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ENSPRYNG is an interleukin-6 (IL-6) receptor antagonist indicated for the treatment of neuromyelitis optica spectrum disorder (NMOSD) in adult patients who are anti-aquaporin-4 (AQP4) antibody positive. ( 1 )